Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2010, Article ID 238491, 6 pages
http://dx.doi.org/10.4061/2010/238491
Research Article

Effects of SR141716A on Cognitive and Depression-Related Behavior in an Animal Model of Premotor Parkinson's Disease

1Departamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina (UFSC), Campus Universitário, Trindade, Bloco D/CCB, P.O. Box 476, 88040-970 Florianópolis, SC, Brazil
2Laboratório de Fisiologia e Farmacologia do Sistema Nervoso Central, Setor de Ciências Biológicas, Universidade Federal do Paraná (UFPR), Centro Politécnico, 81531-980 Curitiba, PR, Brazil

Received 25 March 2010; Revised 16 July 2010; Accepted 31 August 2010

Academic Editor: Alan R. Crossman

Copyright © 2010 M. T. Tadaiesky et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Tolosa and W. Poewe, “Premotor Parkinson disease,” Neurology, vol. 72, no. 7, p. S1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Becker, A. Müller, S. Braune et al., “Early diagnosis of Parkinson's disease,” Journal of Neurology, Supplement, vol. 249, no. 3, pp. 40–48, 2002. View at Google Scholar · View at Scopus
  3. G. Tissingh, P. Bergmans, J. Booij et al., “Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]β-CIT SPECT,” Journal of Neurology, vol. 245, no. 1, pp. 14–20, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. M. T. Tadaiesky, P. A. Dombrowski, C. P. Figueiredo, E. Cargnin-Ferreira, C. Da Cunha, and R. N. Takahashi, “Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease,” Neuroscience, vol. 156, no. 4, pp. 830–840, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Lutz, “Endocannabinoid signals in the control of emotion,” Current Opinion in Pharmacology, vol. 9, no. 1, pp. 46–52, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. C. T. Wotjak, “Role of endogenous cannabinoids in cognition and emotionality,” Mini-Reviews in Medicinal Chemistry, vol. 5, no. 7, pp. 659–670, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Piomelli, “The molecular logic of endocannabinoid signalling,” Nature Reviews Neuroscience, vol. 4, no. 11, pp. 873–884, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Pisani, F. Fezza, S. Galati et al., “High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients,” Annals of Neurology, vol. 57, no. 5, pp. 777–779, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. V. Di Marzo, M. P. Hill, T. Bisogno, A. R. Crossman, and J. M. Brotchie, “Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease,” FASEB Journal, vol. 14, no. 10, pp. 1432–1438, 2000. View at Google Scholar · View at Scopus
  10. P. Gubellini, B. Picconi, M. Bari et al., “Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission,” Journal of Neuroscience, vol. 22, no. 16, pp. 6900–6907, 2002. View at Google Scholar · View at Scopus
  11. E. Fernandez-Espejo, I. Caraballo, F. R. de Fonseca et al., “Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism,” Neurobiology of Disease, vol. 18, no. 3, pp. 591–601, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. González, C. Scorticati, M. García-Arencibia, R. de Miguel, J. A. Ramos, and J. Fernández-Ruiz, “Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease,” Brain Research, vol. 1073-1074, no. 1, pp. 209–219, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. van der Stelt, S. H. Fox, M. Hill et al., “A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease,” FASEB Journal, vol. 19, no. 9, pp. 1140–1142, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. X. Cao, L. Liang, J. R. Hadcock et al., “Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated rhesus monkeys,” Journal of Pharmacology and Experimental Therapeutics, vol. 323, no. 1, pp. 318–326, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Mackie, “Distribution of cannabinoid receptors in the central and peripheral nervous system,” Handbook of Experimental Pharmacology, no. 168, pp. 299–325, 2005. View at Google Scholar · View at Scopus
  16. G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, San Diego, Calif, USA, 5th edition, 2005.
  17. R. D. Porsolt, G. Anton, N. Blavet, and M. Jalfre, “Behavioural despair in rats: a new model sensitive to antidepressant treatments,” European Journal of Pharmacology, vol. 47, no. 4, pp. 379–391, 1978. View at Google Scholar · View at Scopus
  18. R. D. S. Prediger and R. N. Takahashi, “Ethanol improves short-term social memory in rats. Involvement of opioid and muscarinic receptors,” European Journal of Pharmacology, vol. 462, no. 1–3, pp. 115–123, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Griebel, J. Stemmelin, and B. Scatton, “Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents,” Biological Psychiatry, vol. 57, no. 3, pp. 261–267, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. L. P. Shearman, K. M. Rosko, R. Fleischer et al., “Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice,” Behavioural Pharmacology, vol. 14, no. 8, pp. 573–582, 2003. View at Google Scholar · View at Scopus
  21. E. T. Tzavara, R. J. Davis, K. W. Perry et al., “The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions,” British Journal of Pharmacology, vol. 138, no. 4, pp. 544–553, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Herkenham, A. B. Lynn, B. R. de Costa, and E. K. Richfield, “Neuronal localization of cannabinoid receptors in the basal ganglia of the rat,” Brain Research, vol. 547, no. 2, pp. 267–274, 1991. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Y. Meltzer, L. Arvanitis, D. Bauer, and W. Rein, “Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder,” American Journal of Psychiatry, vol. 161, no. 6, pp. 975–984, 2004. View at Publisher · View at Google Scholar
  24. R. E. Hampson and S. A. Deadwyler, “Cannabinoids, hippocampal function and memory,” Life Sciences, vol. 65, no. 6-7, pp. 715–723, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Lutz, “The endocannabinoid system and extinction learning,” Molecular Neurobiology, vol. 36, no. 1, pp. 92–101, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. S. A. Deadwyler, A. V. Goonawardena, and R. E. Hampson, “Short-term memory is modulated by the spontaneous release of endocannabinoids: evidence from hippocampal population codes,” Behavioural Pharmacology, vol. 18, no. 5-6, pp. 571–580, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Micale, L. Cristino, A. Tamburella et al., “Enhanced cognitive performance of dopamine D3 receptor " knock-out" mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems,” Pharmacological Research, vol. 61, no. 6, pp. 531–536, 2010. View at Publisher · View at Google Scholar
  28. J.-P. Terranova, J.-J. Storme, N. Lafon et al., “Improvement of memory in rodents by the selective GB1 cannabinoid receptor antagonist, SR 141716,” Psychopharmacology, vol. 126, no. 2, pp. 165–172, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. J. M. Brotchie, “CB1 cannabinoid receptor signalling in Parkinson's disease,” Current Opinion in Pharmacology, vol. 3, no. 1, pp. 54–61, 2003. View at Publisher · View at Google Scholar · View at Scopus